Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01340625
Recruitment Status : Completed
First Posted : April 22, 2011
Results First Posted : May 25, 2011
Last Update Posted : May 25, 2011
Sponsor:
Information provided by:
Teva Pharmaceuticals USA

Brief Summary:
This study compared the relative bioavailability (rate and extent of absorption) of 0.4 mg/35 mcg Norethindrone and Ethinyl Estradiol Chewable Tablets by Teva Pharmaceuticals, USA with that of 0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets manufactured by Warner Chilcott Company, Inc., following a single oral dose (2 * 0.4 mg/35 mcg chewable tablets) in healthy female adult volunteers administered under fasting conditions.

Condition or disease Intervention/treatment Phase
Bioequivalence Drug: Norethindrone/Ethinyl Estradiol Drug: Ovcon® 35 Fe Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Relative Bioavailability Study of 0.4 mg/35 Mcg Norethindrone and Ethinyl Estradiol Chewable Tablets Under Fasting Conditions
Study Start Date : December 2006
Actual Primary Completion Date : January 2007
Actual Study Completion Date : January 2007


Arm Intervention/treatment
Experimental: Investigational Test Product
Norethindrone/Ethinyl Estradiol 0.4 mg/35 mcg Chewable Tablets (Teva)
Drug: Norethindrone/Ethinyl Estradiol
0.4 mg/35 mcg Chewable Tablets
Other Name: Zeosa®

Active Comparator: Reference Listed Drug
Ovcon® 35 Fe 0.4 mg/35 mcg Chewable Tablets (Warner Chilcott)
Drug: Ovcon® 35 Fe
0.4 mg/35 mcg Chewable Tablets
Other Names:
  • Femcon® Fe
  • Norethindrone/Ethinyl Estradiol (generic name)




Primary Outcome Measures :
  1. Cmax of Norethindrone [ Time Frame: Blood samples collected over a 60 hour period. ]
    Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma).

  2. AUC0-t of Norethindrone [ Time Frame: Blood samples collected over a 60 hour period. ]
    Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).

  3. AUC0-inf of Norethindrone [ Time Frame: Blood samples collected over a 60 hour period. ]
    Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity).

  4. Cmax of Ethinyl Estradiol [ Time Frame: Blood samples collected over a 60 hour period. ]
    Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma).

  5. AUC0-t of Ethinyl Estradiol [ Time Frame: Blood samples collected over a 60 hour period. ]
    Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).

  6. AUC0-inf of Ethinyl Estradiol [ Time Frame: Blood samples collected over a 60 hour period. ]
    Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Volunteers who have been informed of the nature of the study and agree to read, review, and sign the informed consent document prior to Period I dosing.
  • Volunteers who have completed the screening process within 28 days prior to Period I dosing.
  • Volunteers who are healthy adult women 18-35 years of age, inclusive, at the time of dosing.
  • Volunteers who have a body mass index (BMI) between 19-30 kg/m2, inclusive, and weight at least 110 lbs.
  • Volunteers who are healthy as documented by the medical history, physical examination, vital sign assessments, 12-lead electrocardiogram, clinical laboratory assessments, and by general observations. The physical examination will also include a gynecological exam. If the subject has completed an acceptable Papanicolaou smear and gynecological exam in the previous 12 months and documentation of acceptable results are provided, both will be deferred. Any abnormalities/deviations from the normal range that might be considered clinically relevant by the study physician and investigator will be evaluated for individual cases, documented in study files, and agreed upon by both the study physician and investigator prior to enrolling the volunteer in this study and for continued enrollment.
  • Volunteers must practice an acceptable non-hormonal birth control method as judged by the investigator(s) at least 14 days prior to Period I dosing, throughout the study, and until 14 days after second period dosing.

Exclusion Criteria:

  • Volunteers who report receiving any investigational drug within 30 days prior to Period I dosing.
  • Volunteers who report taking any oral contraceptives including estrogen and progestin combined pills and progestin only pills or patch within 28 days prior to Period I dosing, using injectable contraceptives within 6 months of first period dosing.
  • Volunteers who have ever had progestational hormone implants.
  • Volunteers who report any presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic systems or psychiatric disease as determined by the clinical investigator(s).
  • Volunteers who report any presence or history of migraines or severe headaches.
  • Volunteers who have systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 45 or over 90 mmHg will be excluded from the study.
  • Volunteers who have a history of thrombotic disorders or have ever had cerebrovascular accident or transient ischemic attacks.
  • Volunteers with a history of breast cancer or undiagnosed breast nodules, active malignancies or undiagnosed vaginal bleeding.
  • Volunteers having other conditions that may be aggravated by fluid retention (as determined by principal investigator).
  • Volunteers who have a history of jaundice with previous use of oral contraceptives or any other kinds of hormonal contraceptives.
  • Volunteers whose clinical laboratory test values fall outside the accepted reference range and when confirmed on re-examination is deemed to be clinically significant.
  • Volunteers who demonstrate a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
  • Volunteers who report a history of allergic response(s) to norethindrone/ethinyl estradiol or progestin/estrogens or related drugs.
  • Volunteers who report the use of any systemic prescription medication in the 14 days prior to Period I dosing (with the exception of hormonal contraceptives).
  • Volunteers with a history of clinically significant allergies including drug allergies.
  • Volunteers who report a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
  • Volunteers who report a history of drug or alcohol addiction or abuse within the past year.
  • Volunteers who demonstrate a positive drug abuse screen for this study prior to Period I dose administration.
  • Volunteers who currently use or have used tobacco products within 30 days prior to Period I dosing.
  • Volunteers who report donating greater that 150 mL of blood within 30 days prior to Period I dosing. All subjects will be advised not to donate blood for 4 weeks after completing the study.
  • Volunteers who report donating plasma within 30 days prior to Period I dosing. All subjects will be advised not to donate plasma for 4 weeks after completing the study.
  • Volunteers who demonstrate a positive pregnancy screen.
  • Volunteers who are currently pregnant of breastfeeding.
  • Volunteers who are using or have used within the 3 months preceding Period I dosing any vaginally administered estrogen or progestin-containing products.
  • Any volunteer who engages in unprotected sexual intercourse during the time interval starting 14 days prior to first period dosing and until 14 days after the Period II dosing.
  • Volunteers who have had a hysterectomy or oophorectomy (unilateral or bilateral).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01340625


Locations
Layout table for location information
United States, North Dakota
PRACS Institute, Ltd.
Fargo, North Dakota, United States, 58104
Sponsors and Collaborators
Teva Pharmaceuticals USA

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT01340625     History of Changes
Other Study ID Numbers: R06-1188
First Posted: April 22, 2011    Key Record Dates
Results First Posted: May 25, 2011
Last Update Posted: May 25, 2011
Last Verified: April 2011
Keywords provided by Teva Pharmaceuticals USA:
Healthy Subjects
Additional relevant MeSH terms:
Layout table for MeSH terms
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination
Estradiol
Polyestradiol phosphate
Ethinyl Estradiol
Norethindrone
Norethindrone Acetate
Norinyl
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptives, Oral, Combined
Contraceptives, Oral, Hormonal
Contraceptives, Oral, Sequential